138 related articles for article (PubMed ID: 38022532)
1. Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.
Mahdi HS; Woodall-Jappe M; Singh P; Czuczman MS
Front Immunol; 2023; 14():1268979. PubMed ID: 38022532
[TBL] [Abstract][Full Text] [Related]
2. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.
Ohmachi K; Ando K; Ogura M; Uchida T; Tobinai K; Maruyama D; Namiki M; Nakanishi T
Cancer Sci; 2018 Mar; 109(3):794-802. PubMed ID: 29363235
[TBL] [Abstract][Full Text] [Related]
3. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
5. IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer.
Thibodeaux SR; Barnett BB; Pandeswara S; Wall SR; Hurez V; Dao V; Sun L; Daniel BJ; Brumlik MJ; Drerup J; Padrón Á; Whiteside T; Kryczek I; Zou W; Curiel TJ
Clin Cancer Res; 2021 Jul; 27(13):3661-3673. PubMed ID: 33771857
[TBL] [Abstract][Full Text] [Related]
6. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
[TBL] [Abstract][Full Text] [Related]
7. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
Cheung LS; Fu J; Kumar P; Kumar A; Urbanowski ME; Ihms EA; Parveen S; Bullen CK; Patrick GJ; Harrison R; Murphy JR; Pardoll DM; Bishai WR
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3100-3105. PubMed ID: 30718426
[TBL] [Abstract][Full Text] [Related]
8. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.
Albu DI; Wang Z; Huang KC; Wu J; Twine N; Leacu S; Ingersoll C; Parent L; Lee W; Liu D; Wright-Michaud R; Kumar N; Kuznetsov G; Chen Q; Zheng W; Nomoto K; Woodall-Jappe M; Bao X
Oncoimmunology; 2017; 6(8):e1338239. PubMed ID: 28920002
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Kawai H; Ando K; Maruyama D; Yamamoto K; Kiyohara E; Terui Y; Fukuhara N; Miyagaki T; Tokura Y; Sakata-Yanagimoto M; Igarashi T; Kuroda J; Fujita J; Uchida T; Ishikawa T; Yonekura K; Kato K; Nakanishi T; Nakai K; Matsunaga R; Tobinai K
Cancer Sci; 2021 Jun; 112(6):2426-2435. PubMed ID: 33792128
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
11. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
12. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
13. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
[TBL] [Abstract][Full Text] [Related]
14. Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment.
Jin Y; An X; Mao B; Sun R; Kumari R; Chen X; Shan Y; Zang M; Xu L; Muntel J; Beeler K; Bruderer R; Reiter L; Guo S; Zhou D; Li QX; Ouyang X
Sci Rep; 2022 Feb; 12(1):3278. PubMed ID: 35228603
[TBL] [Abstract][Full Text] [Related]
15. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
16. The triple-drug combination DBDx enhances the antitumor efficacy of PD-1 antibody associated with Treg modulation.
Shan C; Wang Y; Li Y; Yang S; Sheng W; Liu X
J Cancer Res Ther; 2023 Dec; 19(6):1603-1609. PubMed ID: 38156928
[TBL] [Abstract][Full Text] [Related]
17. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
18. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
